Results for the 2nd quarter and first half year 2010
(Thomson Reuters ONE) -
Highlights for the second quarter 2010
(2009 figures in brackets)
· Hexvix revenues increased by 19.6% to NOK 14.2 million (11.9) in Q2 2010
· In May, the FDA approved Cysview (Hexvix) for the US market, triggering an
EUR 10 million (NOK 79.3 million) milestone from GE Healthcare
· Total revenue of NOK 93.5 million (11.9) in Q2 2010, including the
milestone for approval of Cysview
· Net profit of NOK 60.2 million (-12.1) in Q2 2010
· Cash holding of NOK 330.8 million per 30 June 2010
· Established US subsidiary, Photocure Inc. Terry Conrad started as
President in August
Key figures
+---------------------------------+-------+-------+--------+--------+-------+
|Figures in NOK '000 |Q2 2010|Q2 2009|YTD 2010|YTD 2009| 2009|
+---------------------------------+-------+-------+--------+--------+-------+
|Sales revenues | 14 245| 11 907| 28 205| 21 576| 48 428|
+---------------------------------+-------+-------+--------+--------+-------+
|Signing fee & milestone revenues | 79 300| 0| 83 440| 0| 0|
+---------------------------------+-------+-------+--------+--------+-------+
|Total revenues | 93 545| 11 907| 111 645| 21 576| 48 428|
+---------------------------------+-------+-------+--------+--------+-------+
|Gross profit | 91 117| 10 621| 107 583| 19 498| 42 887|
+---------------------------------+-------+-------+--------+--------+-------+
|Research and development expenses| 19 996| 20 373| 39 261| 30 916| 78 980|
+---------------------------------+-------+-------+--------+--------+-------+
|Sales and marketing expenses | 7 431| 5 992| 15 568| 12 197| 24 984|
+---------------------------------+-------+-------+--------+--------+-------+
|Operating result (EBIT) | 58 764|-23 310| 43 036| -36 804|-78 952|
+---------------------------------+-------+-------+--------+--------+-------+
|Net profit/loss | 60 244|-20 900| 46 379| -20 706|312 382|
+---------------------------------+-------+-------+--------+--------+-------+
|Earnings per share, diluted (NOK)| 2.72| -0.55| 2.09| -0.94| 3.46|
+---------------------------------+-------+-------+--------+--------+-------+
Please find the full financial report enclosed.
Photocure ASA's results for the second quarter 2010 will be presented at
Shippingklubben, Oslo, Norway, today at 11:30 am CET by the President and CEO
Kjetil Hestdal and CFO Christian Fekete. The presentation will be transferred
live via webcast.
For further information, please contact
President & CEO Kjetil Hestdal, Tel: + 47 913 19 535, email: kh(at)photocure.no
CFO Christian Fekete, Tel: + 47 916 42 938 email: cf(at)photocure.no
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock
Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical
devices for the photodynamic treatment and diagnosis of cancer and selected
dermatology indications.
Photocure's commercial activities include its own marketing and sales
organisations in selected markets as well as partnerships with leading
pharmaceutical companies on a regional or global basis.
Photocure has one proprietary pharmaceutical product on the market: Hexvix®, for
the diagnosis of bladder cancer. Hexvix® is approved in EU and in the US. In
addition, the company has developed a proprietary light source, which is used in
combination with Visonac(TM) cream. Through worldwide studies, Photocure is
continuously testing its products for new indications, and the aim is to develop
a pipeline of follow-on products based on the Photocure Technology(TM) platform.
For more information about Photocure, visit our website at www.photocure.com.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1438784]
Results 2Q10 and 1H10:
http://hugin.info/131151/R/1438784/383219.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Photocure ASA via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 19.08.2010 - 08:01 Uhr
Sprache: Deutsch
News-ID 39804
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Results for the 2nd quarter and first half year 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Photocure ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
